Dermata Therapeutics, Inc. (DRMAW) 是一家上市公司 属于 医疗保健 板块，经营于 生物科技 行业. 公司总部位于 San Diego, CA, 美国. 现任CEO为 Gerald T. Proehl.
DRMAW 拥有 IPO日期为 2021-08-13, 8 名全职员工, 在 NASDAQ Capital Marke, 市值为 $7.57K.
Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the treatment of medical and aesthetic skin conditions. The company's lead product candidate is DMT310, a once-weekly topical product that is under clinical development for the treatment of acne vulgaris, psoriasis vulgaris, and papulopustular rosacea. It is also developing DMT410 for the treatment of hyperhidrosis and aesthetic conditions. The company was founded in 2014 and is headquartered in San Diego, California.
